Literature DB >> 35302046

Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Victoria M Golub1, Doodipala Samba Reddy2.   

Abstract

Post-traumatic epilepsy (PTE) is one of the most devastating long-term, network consequences of traumatic brain injury (TBI). There is currently no approved treatment that can prevent onset of spontaneous seizures associated with brain injury, and many cases of PTE are refractory to antiseizure medications. Post-traumatic epileptogenesis is an enduring process by which a normal brain exhibits hypersynchronous excitability after a head injury incident. Understanding the neural networks and molecular pathologies involved in epileptogenesis are key to preventing its development or modifying disease progression. In this article, we describe a critical appraisal of the current state of PTE research with an emphasis on experimental models, molecular mechanisms of post-traumatic epileptogenesis, potential biomarkers, and the burden of PTE-associated comorbidities. The goal of epilepsy research is to identify new therapeutic strategies that can prevent PTE development or interrupt the epileptogenic process and relieve associated neuropsychiatric comorbidities. Therefore, we also describe current preclinical and clinical data on the treatment of PTE sequelae. Differences in injury patterns, latency period, and biomarkers are outlined in the context of animal model validation, pathophysiology, seizure frequency, and behavior. Improving TBI recovery and preventing seizure onset are complex and challenging tasks; however, much progress has been made within this decade demonstrating disease modifying, anti-inflammatory, and neuroprotective strategies, suggesting this goal is pragmatic. Our understanding of PTE is continuously evolving, and improved preclinical models allow for accelerated testing of critically needed novel therapeutic interventions in military and civilian persons at high risk for PTE and its devastating comorbidities. SIGNIFICANCE STATEMENT: Post-traumatic epilepsy is a chronic seizure condition after brain injury. With few models and limited understanding of the underlying progression of epileptogenesis, progress is extremely slow to find a preventative treatment for PTE. This study reviews the current state of modeling, pathology, biomarkers, and potential interventions for PTE and comorbidities. There's new optimism in finding a drug therapy for preventing PTE in people at risk, such as after traumatic brain injury, concussion, and serious brain injuries, especially in military persons.
Copyright © 2022 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35302046      PMCID: PMC8973512          DOI: 10.1124/pharmrev.121.000375

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  410 in total

1.  Measuring Histone Deacetylase Inhibition in the Brain.

Authors:  Doodipala Samba Reddy; Xin Wu; Victoria M Golub; W Mohaiza Dashwood; Roderick H Dashwood
Journal:  Curr Protoc Pharmacol       Date:  2018-06-07

Review 2.  Pathophysiology and Treatment of Memory Dysfunction After Traumatic Brain Injury.

Authors:  Rosalia Paterno; Kaitlin A Folweiler; Akiva S Cohen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

3.  Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models.

Authors:  Nigel C Jones; Thanh Nguyen; Niall M Corcoran; Dennis Velakoulis; Tracy Chen; Robert Grundy; Terence J O'Brien; Christopher M Hovens
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

Review 4.  Cumulative effects of repetitive mild traumatic brain injury.

Authors:  Julian E Bailes; Matthew L Dashnaw; Anthony L Petraglia; Ryan C Turner
Journal:  Prog Neurol Surg       Date:  2014-06-06

5.  Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  Neuropharmacology       Date:  2018-11-22       Impact factor: 5.250

Review 6.  Animal models in burn research.

Authors:  A Abdullahi; S Amini-Nik; M G Jeschke
Journal:  Cell Mol Life Sci       Date:  2014-04-09       Impact factor: 9.261

7.  Mossy fiber synaptic reorganization in the epileptic human temporal lobe.

Authors:  T Sutula; G Cascino; J Cavazos; I Parada; L Ramirez
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

8.  Blood-brain barrier disruption in post-traumatic epilepsy.

Authors:  O Tomkins; I Shelef; I Kaizerman; A Eliushin; Z Afawi; A Misk; M Gidon; A Cohen; D Zumsteg; A Friedman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11-08       Impact factor: 10.154

9.  A comparison of publication to TBI burden ratio of low- and middle-income countries versus high-income countries: how can we improve worldwide care of TBI?

Authors:  Maria Pia Tropeano; Riccardo Spaggiari; Hernán Ileyassoff; Kee B Park; Angelos G Kolias; Peter J Hutchinson; Franco Servadei
Journal:  Neurosurg Focus       Date:  2019-11-01       Impact factor: 4.047

10.  Functional Integration of Adult-Born Hippocampal Neurons after Traumatic Brain Injury(1,2,3).

Authors:  Laura E Villasana; Kristine N Kim; Gary L Westbrook; Eric Schnell
Journal:  eNeuro       Date:  2015-09-28
View more
  3 in total

Review 1.  Molecular Mechanisms of Epilepsy: The Role of the Chloride Transporter KCC2.

Authors:  Giorgio Belperio; Claudia Corso; Carlos B Duarte; Miranda Mele
Journal:  J Mol Neurosci       Date:  2022-07-12       Impact factor: 2.866

Review 2.  TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.

Authors:  Jian Luo
Journal:  Biomedicines       Date:  2022-05-23

Review 3.  Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders.

Authors:  Doodipala Samba Reddy; Hasara Nethma Abeygunaratne
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.